Breaking into Merck's CCK Patents: the Starting Point of PNB Vesper Life Science to Design and Develop Cholecystokinin(CCK)-Antagonists as Targeted Chemotherapeutics
Open Access
- 29 March 2018
- journal article
- Published by Lupine Publishers LLC in Drug Designing & Intellectual Properties International Journal
- Vol. 1 (2), 001-0013
- https://doi.org/10.32474/ddipij.2018.01.000106